New combo therapy aims to outsmart hard-to-treat breast cancer

This early-stage trial tests whether giving the drug bortezomib first can make metastatic triple-negative breast cancer more sensitive to two other drugs (pembrolizumab and cisplatin). About 20 women with advanced breast cancer that has already been treated with standard chemotherapy will receive this sequence. The goal is to see if the tumors shrink or stop growing, and to study the cancer's genetic changes.